Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Lung Neoplasms 10Burkitt Lymphoma 9Leukemia, Myeloid, Acute 8Lymphoma 7Hodgkin Disease 6Carcinoma, Non-Small-Cell Lung 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Multiple Myeloma 5Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Sarcoma, Ewing 3Sarcoma 3Rhabdomyosarcoma 3Rhabdoid Tumor 3Retinoblastoma 3Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neuroblastoma 3Neoplasms, Germ Cell and Embryonal 3Myelodysplastic Syndromes 3Medulloblastoma 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Leukemia 3Immunoblastic Lymphadenopathy 3Seminoma 2

Interventions

pembrolizumab 1durvalumab 1dostarlimab 1atezolizumab 1Etoposide 1Carboplatin 1AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Bites and Stings × Etoposide × Clear all
NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Amgen

Phase 1 Active not recruiting
184 enrolled
Thoracic

Bites and Stings, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡